Literature DB >> 16030422

Statistics on cancer in China: cancer registration in 2002.

L Yang1, D M Parkin, S Whelan, S Zhang, Y Chen, F Lu, L Li.   

Abstract

The objective of this study was to determine how many population-based cancer registries exist in China, what methods are being used, and the statistical data that are available from them, and to identify future needs with respect to technical support. A two-stage survey was conducted in 2002 at provincial and cancer registry level. Based on the questionnaire used in these two stages, the basic distribution and descriptive information on population-based cancer registry practices in China are addressed. There are 48 cancer registries in China, covering 73 million people (5.7% of the total population of China in 2000). The oldest three registries are LinZhou, ShangHai and QiDong. There are marked variations in practice between registries, with respect to data collection, data management and coding. Differences are also found in administrative aspects and sources of financial support. In conclusion, this first national survey of Chinese cancer registry practice provides a benchmark against which development and standardization can be evaluated in the future. The survey suggests that lack of qualified personnel, insufficient funding support and lack of stability of the population are major problems in carrying out registration work in China. It also indicates several ways in which registry practice, and hence availability and quality of incidence and survival data can be improved.

Entities:  

Mesh:

Year:  2005        PMID: 16030422     DOI: 10.1097/00008469-200508000-00004

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  20 in total

1.  There still a long way to go for cancer registration in China.

Authors:  Miao He; Qing Zhang
Journal:  Ann Transl Med       Date:  2014-07

2.  Prevalence of gastric cancer versus colorectal cancer in Asians with a positive fecal occult blood test.

Authors:  Lukejohn W Day; John P Cello; Ma Somsouk; John M Inadomi
Journal:  Indian J Gastroenterol       Date:  2011-09-23

Review 3.  Human behaviors determine health: strategic thoughts on the prevention of chronic non-communicable diseases in China.

Authors:  Zhi-Yin Yang; Zhen Yang; Lifang Zhu; Chengxuan Qiu
Journal:  Int J Behav Med       Date:  2011-12

4.  Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells.

Authors:  Lei Lv; Xing-Yuan Xiao; Zhao-Hui Gu; Fu-Qing Zeng; Lu-Qi Huang; Guo-Song Jiang
Journal:  Mol Cell Biochem       Date:  2010-09-09       Impact factor: 3.396

5.  Current status of gynecological cancer in China.

Authors:  Kidong Kim; Rongyu Zang; Seok-Cheol Choi; Sang-Young Ryu; Jae Weon Kim
Journal:  J Gynecol Oncol       Date:  2009-06-29       Impact factor: 4.401

6.  A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.

Authors:  Yi Shi; Lin Sun; Ge Chen; Dongyan Zheng; Li Li; Wanguo Wei
Journal:  Target Oncol       Date:  2015-04-29       Impact factor: 4.493

7.  Parthenolide induces apoptosis and lytic cytotoxicity in Epstein-Barr virus-positive Burkitt lymphoma.

Authors:  Yuan Li; Yongli Zhang; Mingming Fu; Qin Yao; Huiqin Zhuo; Quanyi Lu; Xiaoqing Niu; Peng Zhang; Yihua Pei; Kejie Zhang
Journal:  Mol Med Rep       Date:  2012-06-20       Impact factor: 2.952

8.  Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma.

Authors:  Guiping Wang; Yun Ye; Xiaoqin Yang; Hongying Liao; Canguo Zhao; Shuang Liang
Journal:  PLoS One       Date:  2011-01-21       Impact factor: 3.240

9.  Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer.

Authors:  Xia Xu; Yan Wang; Fang Wang; Lizhou Jia; Yiqin Zhou; Fei Deng; Junwei Qu; Bifang Zhou; Aifeng Meng; Bole Fu; Xiaoxiang Chen; Zhiying Qian; Jinhua Wang
Journal:  J Ovarian Res       Date:  2013-04-25       Impact factor: 4.234

10.  Noncoding RNAs and Cancer.

Authors:  Mozhgan Moslemi Naeini; Ali M Ardekani
Journal:  Avicenna J Med Biotechnol       Date:  2009-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.